LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

Cerus Corp

Geschlossen

BrancheGesundheitswesen

1.28 -0.78

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.27

Max

1.31

Schlüsselkennzahlen

By Trading Economics

Einkommen

2M

-5.7M

Verkäufe

9.2M

52M

EPS

-0.04

Gewinnspanne

-10.897

Angestellte

614

EBITDA

2.7M

-3.1M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+238.35% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

29. Okt. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

2.6M

251M

Vorheriger Eröffnungskurs

2.06

Vorheriger Schlusskurs

1.28

Nachrichtenstimmung

By Acuity

23%

77%

62 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

Cerus Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

8. Sept. 2025, 23:59 UTC

Akquisitionen, Fusionen, Übernahmen

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8. Sept. 2025, 22:02 UTC

Wichtige Markttreiber

Microsoft Signs $17.4 Billion AI Deal With Nebius

8. Sept. 2025, 17:01 UTC

Wichtige Markttreiber

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8. Sept. 2025, 17:01 UTC

Wichtige Markttreiber

Tron Shares Rise After New Investment From Bravemorning

8. Sept. 2025, 16:14 UTC

Wichtige Markttreiber

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8. Sept. 2025, 16:13 UTC

Wichtige Markttreiber

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8. Sept. 2025, 23:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. Sept. 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

8. Sept. 2025, 23:12 UTC

Market Talk

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8. Sept. 2025, 22:56 UTC

Market Talk

Worst May Be Over for New Zealand Retailers -- Market Talk

8. Sept. 2025, 22:23 UTC

Market Talk

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8. Sept. 2025, 21:51 UTC

Market Talk

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8. Sept. 2025, 21:47 UTC

Wichtige Markttreiber

Microsoft Signs $17.4B AI Deal With Nebius

8. Sept. 2025, 21:33 UTC

Akquisitionen, Fusionen, Übernahmen

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8. Sept. 2025, 21:20 UTC

Akquisitionen, Fusionen, Übernahmen

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8. Sept. 2025, 21:19 UTC

Akquisitionen, Fusionen, Übernahmen

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8. Sept. 2025, 21:18 UTC

Akquisitionen, Fusionen, Übernahmen

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8. Sept. 2025, 20:50 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Tech, Media & Telecom Roundup: Market Talk

8. Sept. 2025, 19:33 UTC

Market Talk

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8. Sept. 2025, 19:22 UTC

Market Talk

U.S. Natural Gas Futures Settle Higher -- Market Talk

8. Sept. 2025, 19:02 UTC

Market Talk

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8. Sept. 2025, 18:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. Sept. 2025, 18:24 UTC

Market Talk

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8. Sept. 2025, 17:29 UTC

Market Talk

Mexican Inflation Seen Little Changed in August -- Market Talk

8. Sept. 2025, 16:59 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8. Sept. 2025, 16:36 UTC

Market Talk

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8. Sept. 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8. Sept. 2025, 16:16 UTC

Ergebnisse

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8. Sept. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8. Sept. 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Cerus Corp Prognose

Kursziel

By TipRanks

238.35% Vorteil

12-Monats-Prognose

Durchschnitt 4.5 USD  238.35%

Hoch 5 USD

Tief 4 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cerus Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

3

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

1.3 / 1.36Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

62 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Cerus Corp

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.
help-icon Live chat